Led · Series C · Aug 2021

MediTrust is a Shanghai-based private healthcare payor founded in 2017 and led by founder and CEO Seth Zhang. It leverages proprietary integrated platforms to serve healthcare and insurance companies, delivering comprehensive healthcare products and services aimed at lowering medical costs. A core service, Care2Pay, partners with more than 50 pharmaceutical and insurance companies and over 2,000 DTP pharmacies, with national coverage in over 400 cities. Care2Pay enables millions of patients with cancer, chronic, and rare diseases to access innovative drugs more affordably; in the first half of 2021 it helped patients and families save over RMB300 million in healthcare expenditures. MediTrust also collaborates with insurers to launch municipal health insurance products in more than 40 cities, including Beijing and Shanghai, and has been instrumental in Shanghai’s Huhuibao coverage expansion.

Participated · Series D · Sep 2020

InventisBio is a Shanghai, China–based clinical-stage biotech focused on discovering and developing proprietary small-molecule drugs for cancer and metabolic diseases. Led by Dr. Yaolin Wang (Chairman and CEO), the company currently has three drug candidates in mid- to late-stage clinical development and one new candidate that recently entered a global Phase I study. Its lead programs include D-0502, an oral selective estrogen receptor degrader (SERD) and antagonist for hormone receptor–positive breast cancer, and BPI-D0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. BPI-D0316's China rights have been out-licensed to Betta Pharma and the product is undergoing registration trials for first- and second-line treatment of EGFR-mutated non-small cell lung cancer. The company is also developing D-0120 for gout. Plans include advancing current programs through Phase II studies in China and the United States and expanding the product pipeline and team. InventisBio is a clinical-stage biotech led by Dr. Yaolin Wang focused on discovering and developing novel therapeutics against cancer and metabolic diseases. The company has three drug candidates in clinical development for breast cancer, lung cancer and gout. It licensed China rights to its third-generation EGFR‑T790M inhibitor D‑0316 to Betta Pharma in December 2018 and is co-developing D‑0316 in a phase 2 trial for non-small cell lung cancer. InventisBio intends to use the new funds to accelerate development of its clinical candidates into phase 2 trials and to advance other drug candidates into the clinic. Prior financings noted in the articles include angel investment from Beautiful Mind Capital, a Series A led by Lilly Asia Venture in 2016 and a Series B led by OrbiMed Asia with participation from LAV in 2017. InventisBio is a Shanghai-based biotech dedicated to the discovery and development of novel medicines. Its pipeline includes small-molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also developing agents intended to be combined with immune-oncology targeted therapies such as PD-1 antibodies. Three drug candidates were expected to enter Phase 1 clinical trials in the US and China in 2017. InventisBio was co-founded by Chairman and CEO Dr. Yaolin Wang and other scientists with prior experience at Merck and Schering-Plough. Prior financings and the recent Series B provide capital to advance its preclinical and early-clinical programs.

Led · Series C · Jun 2020

Everest Medicines focuses on in-licensing, developing and commercializing transformative pharmaceutical products for Greater China and Asian markets. The company has built a portfolio of eight potentially first-in-class or best-in-class molecules, with several programs in late-stage development and multiple assets in registrational or global Phase 3 trials. Key assets include Trodelvy (sacituzumab govitecan) with US approval and a CTA approval in China for mTNBC, Xerava (eravacycline) with US/EU approval and a Phase 3 trial in China, and late‑stage programs such as etrasimod, taniborbactam, ralinepag XR, nefecon, FGF401 and SPR206. Everest plans to use proceeds from its financing to advance clinical development across its pipeline and to build commercial infrastructure for the next phase of growth. The company was incubated by CBC Group and has publicly noted rapid progress since its inception in late 2017.

Participated · Equity · Apr 2020

RemeGen is a biopharmaceutical company with integrated capabilities in research, discovery, clinical development, manufacturing and commercialization of biologic drugs. Founded in 2008 and led by CEO Jianmin Fang, the company focuses on innovative biologics for autoimmune diseases, cancer, and ophthalmology. It has built a pipeline of over 10 innovative molecules, with two molecules spanning five indications currently in Phase III or pivotal trials in China, and one new drug application filed. Its lead molecules are RC18 (telitacicept), a fusion protein with an NDA filed in China for systemic lupus erythematosus and additional Phase II/III programs across six autoimmune indications, and RC48, a HER2 antibody‑drug conjugate in pivotal trials for gastric and urothelial cancers. RemeGen intends to use funds to continue developing its early‑stage drug discovery platform, expand manufacturing facilities, and advance commercialization of RC18 and RC48. The company recently closed an approximately $100M private financing round to support those efforts.

Participated · Series A · Nov 2018

Alphamab Oncology develops multifunctional biologics for cancer using protein engineering and proprietary platforms, including Bispecific and Mix-mAb platforms and single-domain antibodies. Led by Dr. Ting Xu (Founder, Chairman and CEO), the company is advancing multiple clinical-stage assets. Its pipeline includes KN035 (Envafolimab), a subcutaneous PD-L1 antibody in phase II and phase III trials; KN046, a PD-L1/CTLA-4 bispecific progressing through phase II after phase I trials; KN026, an anti-HER2 bispecific entering phase II in China; and immunomodulator KN019 in phase II. Alphamab has formed partnerships (HEC Research Institute and TOT Biopharm) to develop combination therapies involving KN046. The company plans to use new funds to develop its pipeline, commission a new R&D and manufacturing site, accelerate clinical development of its assets, and prepare for commercial launch of KN035. Financially, Alphamab completed a US$60M Series B in May 2019 following a US$130M Series A in November 2018. Alphamab Oncology is a clinical-stage biopharmaceutical company focused on discovery, development, manufacturing and commercialization of cancer therapeutics. Led by Dr. Xu Ting, the company uses multiple in-house platforms including bispecifics, protein engineering and antibody screening. Its oncology/immunology pipeline includes KN035 (Envafolimab), a subcutaneously administered PD-L1 antibody in pivotal trials in China; KN046, a PD-L1–CTLA-4 bispecific in phase I in Australia with planned phase I/II trials in China and BLA-enabling studies; and KN026, an anti-HER2 bispecific in phase I in China. Alphamab plans to use the financing to advance global clinical development—especially its second-generation immuno-oncology medicine—expand global clinical and commercial teams, and complete construction of its biologics manufacturing facilities. The company completed a Series A financing of more than $100 million to support these objectives.